1.46
Schlusskurs vom Vortag:
$1.55
Offen:
$1.5
24-Stunden-Volumen:
2.90M
Relative Volume:
0.56
Marktkapitalisierung:
$316.12M
Einnahmen:
$95,000
Nettoeinkommen (Verlust:
$-327.27M
KGV:
-0.6887
EPS:
-2.12
Netto-Cashflow:
$-239.25M
1W Leistung:
-13.10%
1M Leistung:
-25.13%
6M Leistung:
-47.86%
1J Leistung:
-67.34%
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Firmenname
Allogene Therapeutics Inc
Sektor
Branche
Telefon
(650) 457-2700
Adresse
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Vergleichen Sie ALLO mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ALLO
Allogene Therapeutics Inc
|
1.46 | 316.12M | 95,000 | -327.27M | -239.25M | -2.12 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-14 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
2024-08-08 | Fortgesetzt | Oppenheimer | Outperform |
2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
2024-01-05 | Herabstufung | Guggenheim | Buy → Neutral |
2024-01-05 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
2023-12-08 | Eingeleitet | Citigroup | Buy |
2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
2023-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
2023-01-06 | Hochstufung | Robert W. Baird | Neutral → Outperform |
2022-12-12 | Herabstufung | BofA Securities | Buy → Underperform |
2022-08-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
2022-07-15 | Hochstufung | Goldman | Neutral → Buy |
2022-06-03 | Eingeleitet | Robert W. Baird | Neutral |
2022-02-28 | Bestätigt | B. Riley Securities | Buy |
2021-10-20 | Eingeleitet | Cowen | Outperform |
2021-10-08 | Herabstufung | Goldman | Buy → Neutral |
2021-10-08 | Herabstufung | Stifel | Buy → Hold |
2021-09-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
2021-06-21 | Fortgesetzt | Jefferies | Buy |
2021-05-20 | Hochstufung | Truist | Hold → Buy |
2021-05-14 | Eingeleitet | B. Riley Securities | Buy |
2021-01-26 | Hochstufung | Stifel | Hold → Buy |
2020-12-10 | Fortgesetzt | H.C. Wainwright | Buy |
2020-11-24 | Eingeleitet | BofA Securities | Buy |
2020-10-23 | Eingeleitet | RBC Capital Mkts | Outperform |
2020-06-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
2020-05-29 | Bestätigt | H.C. Wainwright | Buy |
2020-05-19 | Hochstufung | ROTH Capital | Neutral → Buy |
2020-05-15 | Hochstufung | Guggenheim | Neutral → Buy |
2020-05-14 | Bestätigt | H.C. Wainwright | Buy |
2020-05-14 | Herabstufung | SunTrust | Buy → Hold |
2020-04-13 | Eingeleitet | SunTrust | Buy |
2020-03-13 | Eingeleitet | H.C. Wainwright | Buy |
2020-03-05 | Eingeleitet | Stifel | Hold |
2020-02-24 | Eingeleitet | Berenberg | Hold |
2019-12-18 | Eingeleitet | JMP Securities | Mkt Outperform |
2019-11-04 | Eingeleitet | Canaccord Genuity | Buy |
2019-08-09 | Eingeleitet | BTIG Research | Buy |
2019-06-05 | Eingeleitet | ROTH Capital | Neutral |
2019-05-31 | Eingeleitet | Guggenheim | Neutral |
2019-05-23 | Eingeleitet | Stifel | Hold |
2019-03-29 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Allogene Therapeutics Inc Aktie (ALLO) Neueste Nachrichten
H.C. Wainwright cuts Allogene stock target to $8, keeps Buy rating By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Allogene stock target to $8, keeps Buy rating - Investing.com India
Allogene Therapeutics CEO sells $91,469 in stock By Investing.com - Investing.com Australia
Allogene Therapeutics CEO sells $91,469 in stock - Investing.com India
Allogene Therapeutics Executives Sell Shares for Tax Obligations - TradingView
Renal Cancer Clinical Pipeline | 75+ Companies, Including - openPR.com
7th Annual Allogeneic Cell Therapies Summit - pharmaphorum
Allogene Therapeutics' SWOT analysis: CAR-T pioneer's stock faces pivotal year - Investing.com
Allogene Therapeutics’ SWOT analysis: CAR-T pioneer’s stock faces pivotal year - Investing.com India
Allogeneic T Cell Therapies Market Set For 9.8% Growth, Reaching $1.9 Billion By 2029 - WhaTech
Allogene upgraded at Citizens after Q4 update - MSN
Allogene Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2024 Earnings Call Transcript - Insider Monkey
Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlights: Financial Challenges Amid ... By GuruFocus - Investing.com Canada
Citizens Capital Markets Upgrades Allogene Therapeutics (ALLO) - Nasdaq
Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlights: Financial Challenges Amid ... - Yahoo
Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlight - GuruFocus.com
Citi maintains Buy on Allogene stock with $8 price target By Investing.com - Investing.com Australia
Allogene stock upgraded at Citizens post Q4 (ALLO:NASDAQ) - Seeking Alpha
Citi maintains Buy on Allogene stock with $8 price target - Investing.com India
Allogene's Q4 Loss Narrower Than Expected, Revenues Nil - Yahoo Finance
Allogene Therapeutics: Q4 Earnings Snapshot - The Wilton Bulletin
Earnings call transcript: Allogene’s Q4 2024 earnings beat expectations By Investing.com - Investing.com South Africa
Earnings call transcript: Allogene’s Q4 2024 earnings beat expectations - Investing.com India
Allogene Therapeutics Inc Q4 Loss Per Share $0.28 -March 13, 2025 at 05:32 pm EDT - Marketscreener.com
Allogene Therapeutics Inc Reports Q4 2024 EPS of -$0.28, Beating Estimates; Revenue Falls Short - GuruFocus.com
Allogene Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
ALLOGENE THERAPEUTICS Earnings Results: $ALLO Reports Quarterly Earnings - Nasdaq
Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update - The Manila Times
Allogene Therapeutics: Q4 Earnings Snapshot -March 13, 2025 at 05:05 pm EDT - Marketscreener.com
Allogene Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain - Yahoo Finance
CAR T-cell Therapy Clinical Trial Pipeline Experiences - GlobeNewswire
Foresight Diagnostics expands Allogene partnership - BizWest
Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update - The Manila Times
When Will Allogene Reveal Its CAR T Progress? Key Earnings Date Set - StockTitan
Allogene Therapeutics Schedules Conference Call and Webcast for Q4 and Full Year 2024 Financial Results on March 13, 2025 - Nasdaq
Foresight Diagnostics Expands Strategic Partnership with Allogene Therapeutics to Advance Joint Development Activities Outside of the U.S. Across Europe, UK, Canada and Australia - The Malaysian Reserve
Allogene Short Interest Reportedly Near 5-Year Lows Amid Growing Retail Optimism: Analyst Sees CAR-T Therapy Promise - MSN
Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities (NASDAQ:ALLO) - Seeking Alpha
Allogene Expands Partnership With Foresight Diagnostics To Advance Cema-Cel Development Globally - Nasdaq
Allogene Therapeutics Announces Participation in March Investor Conference - The Manila Times
Finanzdaten der Allogene Therapeutics Inc-Aktie (ALLO)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):